BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 29605214)

  • 1. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
    Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
    Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study.
    Menéndez R; España PP; Pérez-Trallero E; Uranga A; Méndez R; Cilloniz C; Marimón JM; Cifuentes I; Méndez C; Torres A
    Vaccine; 2017 Sep; 35(39):5264-5270. PubMed ID: 28823622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
    PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
    J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.
    LeBlanc J; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang AL; Gillis HD; Martin I; Demczuk WH; LaFerriere C; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy A; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32188585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
    LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
    Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
    Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil.
    Duarte FG; Barberino MG; da Silva Moreira S; Reis JN; Spinardi JR; de Almeida RS; Allen KE; Alexander-Parrish R; Brim R; de Araújo Neto CA; Moreira ED
    BMJ Open; 2022 Apr; 12(4):e059824. PubMed ID: 35428648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia.
    Isturiz RE; Ramirez J; Self WH; Grijalva CG; Counselman FL; Volturo G; Ostrosky-Zeichner L; Peyrani P; Wunderink RG; Sherwin R; Overcash JS; Oliva SP; File T; Wiemken TL; McLaughlin JM; Pride MW; Gray S; Alexander R; Ford KD; Jiang Q; Jodar L
    Vaccine; 2019 May; 37(25):3352-3361. PubMed ID: 31072732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL
    Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
    BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination.
    Orsi A; Ansaldi F; Trucchi C; Rosselli R; Icardi G
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel.
    Regev-Yochay G; Chowers M; Chazan B; Gonzalez E; Gray S; Zhang Z; Pride M
    Hum Vaccin Immunother; 2018; 14(10):2527-2532. PubMed ID: 30188760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
    Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
    Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
    Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
    Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.
    Principi N; Esposito S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28029140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
    Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, population-based surveillance of the burden of Streptococcus pneumoniae in community-acquired pneumonia in older adults, Chrzanów County, Poland, 2010 to 2012.
    Harat R; Alexander R; Gray S; Gutterman EM; Pluta J; Pride M; Shite S; Fijolek J; Kozub J
    Pneumonol Alergol Pol; 2016; 84(2):95-103. PubMed ID: 27238167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.